Selected stock price target news of the day - February 18th, 2025

By: Matthew Otto

DraftKings Exceeds Q4 Earnings Expectations and Raises 2025 Revenue Guidance

DraftKings reported its fourth quarter results with Q4 earnings per share (EPS) of $0.14, outperforming analyst expectations by $0.15, as the consensus estimate was ($0.01). Revenue for the quarter reached $1.39 billion, aligning with the consensus estimate and reflecting a 13% increase from $1.231 billion in the same period of 2023.

This growth was driven by continued customer engagement, strategic acquisition of Jackpocket Inc., and an expanded Sportsbook product offering, though partially offset by customer-friendly NFL outcomes. Monthly Unique Payers (MUPs) grew by 36% year-over-year to 4.8 million, while Average Revenue per MUP (ARPMUP) declined by 16% to $97 due to the integration of Jackpocket customers and lower Sportsbook hold rates. Excluding Jackpocket’s impact, ARPMUP decreased by 4%.

Looking ahead, DraftKings raised its 2025 revenue guidance midpoint to $6.45 billion, up from the previous $6.4 billion, reflecting an anticipated 35% year-over-year growth. DraftKings reaffirmed its 2025 Adjusted EBITDA guidance range of $900 million to $1.0 billion. DraftKings’ updated revenue outlook of $6.3 billion to $6.6 billion exceeds the consensus estimate of $6.38 billion.

Analysts Raise Price Targets Following Q4 Results

Barclays analyst Brandt Montour maintained an Overweight rating and raised the price target from $50 to $60.
Truist Securities analyst Barry Jonas reiterated a Buy rating while increasing the price target from $50 to $60.
Stifel analyst Jeffrey Stantial kept a Buy rating and lifted the price target from $48 to $57.
Needham analyst Bernie McTernan maintained a Buy rating and raised the price target from $60 to $65.

Which Analyst has the best track record to show on DKNG?

Analyst Brandt Montour (BARCLAYS) currently has the highest performing score on DKNG with 10/13 (76.92%) price target fulfillment ratio. His price targets carry an average of $7.79 (18.46%) potential upside. DraftKings stock price reaches these price targets on average within 25 days.

Ingersoll Rand Reports 2024 Performance but Misses Q4 Estimates; Provides 2025 Guidance

Ingersoll Rand delivered its financial performance in 2024 reporting orders of $1,800 million for the fourth quarter. It is an 8% increase compared to the same period in 2023, and revenues of $1,899 million, up 4%. However, revenue came in below the consensus estimate of $1.93 billion.

Net income attributable to Ingersoll Rand was $230 million, or $0.57 per share, while Adjusted EPS was $0.84, which was $0.01 lower than the analyst estimate of $0.85. Adjusted EBITDA reached $532 million, marking a 6% increase with a margin of 28.0%, up 50 basis points year-over-year.

Ingersoll Rand also generated $526 million in operating cash flow and $491 million in free cash flow, resulting in a free cash flow margin of 26%. As of December 31, 2024, Ingersoll Rand maintained its liquidity position with $4.1 billion. This includes $1.5 billion in cash and $2.6 billion in undrawn credit capacity.

For the full year, Ingersoll Rand reported orders of $7,106 million, a 4% increase from 2023, and revenues of $7,235 million, up 5%. Achieved net income of $839 million, or $2.06 per share, and Adjusted net income of $1,349 million, or $3.29 per share, reflecting an 11% increase. Adjusted EBITDA for the year was $2,018 million, up 13%, with a margin of 27.9%, an improvement of 190 basis points. Ingersoll Rand generated $1,397 million in operating cash flow and $1,248 million in free cash flow, resulting in a 17% free cash flow margin.

Looking ahead, Ingersoll Rand expects 2025 revenue growth of 3% to 5% and Adjusted EBITDA between $2,130 million and $2,190 million, representing a 6% to 9% increase. Ingersoll Rand forecasts 2025 Adjusted EPS in the range of $3.38 to $3.50, compared to the consensus estimate of $3.46, reflecting growth of 3% to 6% over the prior year.

Mixed Analyst Ratings Amid Price Target Adjustments

Baird analyst Michael Halloran maintained an Outperform rating and raised the price target from $105 to $111.
Barclays analyst Julian Mitchell kept an Overweight rating but lowered the price target from $115 to $102.
Stifel analyst Nathan Jones maintained a Hold rating while reducing the price target from $100 to $94.

Which Analyst has the best track record to show on IR?

Analyst Nathan Jones (STIFEL) currently has the highest performing score on IR with 10/14 (71.43%) price target fulfillment ratio. His price targets carry an average of $6.89 (7.40%) potential upside. Ingersoll Rand stock price reaches these price targets on average within 92 days.

Outlook Therapeutics Anticipates 2025 Milestones with LYTENAVA™ Launches and BLA Resubmission

Outlook Therapeutics reported its first-quarter fiscal year 2025 financial results and provided updates on its ONS-5010 / LYTENAVA™ (bevacizumab-vikg) program. It confirmed that the resubmission of its Biologics License Application (BLA) for ONS-5010 is on track for the first quarter of calendar year 2025, with potential U.S. FDA approval expected in the third quarter.

Commercial launches in Germany and the UK are planned for the second quarter of 2025. This marks the first authorized use of an ophthalmic formulation of bevacizumab for treating wet age-related macular degeneration (wet AMD) in these markets. In Europe, over 2.5 million off-label bevacizumab injections are administered annually. Germany alone accounting for approximately 1.6 million anti-VEGF retina injections, presenting a market opportunity for LYTENAVA™.

Financially, Outlook Therapeutics reported a net income of $17.4 million, or $0.72 per share, for the first quarter ending December 31, 2024, compared to a net loss of $11.2 million, or $0.86 per share, for the same period the previous year. The adjusted net loss for the quarter was $21.6 million, including a $40.3 million gain from the change in fair value of convertible promissory notes. As of December 31, 2024, cash and cash equivalents stood at $5.7 million, excluding $17.8 million received from a warrant exercise inducement in January 2025.

Analysts Update Ratings and Price Targets Amid Market Shifts

HC Wainwright & Co. analyst Douglas Tsao maintained a Buy rating but lowered the price target from $30 to $3.
Chardan Capital analyst Daniil Gataulin maintained a Neutral rating and the price target at $3.

Which Analyst has the best track record to show on OTLK?

Analyst Edward Woo (ASCENDIANT) currently has the highest performing score on OTLK with 1/1 (100%) price target fulfillment ratio. His price targets carry an average of $1.11 (284.62%) potential upside. Outlook Therapeutics stock price reaches these price targets on average within 76 days.